Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 10:08 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 697–720 of 1,494 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Patch 2 Clear all
Completed Phase 2 Interventional

A Study of Stereotactic Body Radiation Therapy and Radium (Ra-223) Dichloride in Prostate Cancer That Has Spread to the Bones

NCT05133440
View directory record Official record
Conditions
Prostate Cancer
Interventions
Radium dichloride, PET Scan
Drug · Diagnostic Test
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
7
States / cities
Aurora, Colorado • Basking Ridge, New Jersey • Middletown, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Oct 20, 2026, 10:08 PM EDT
Terminated Phase 3 Interventional

Fentanyl Transdermal Matrix Patch ZR-02-01 to Treat Moderate to Severe Cancer Pain

NCT00126789
View directory record Official record
Conditions
Pain, Cancer
Interventions
Fentanyl Transdermal Matrix Patch ZR-02-01
Drug
Lead sponsor
ZARS Pharma Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
2
States / cities
Loma Linda, California • Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 5, 2012 · Synced Oct 20, 2026, 10:08 PM EDT
Completed Early Phase 1 Interventional

Enhancing Radioiodine (RAI) Incorporation Into BRAF Mutant, RAI-Refractory Thyroid Cancers With the BRAF Inhibitor Vemurafenib: A Pilot Study

NCT02145143
View directory record Official record
Conditions
Thyroid Carcinoma
Interventions
Vemurafenib, serial 124I PET/CT, thyrotropin alpha
Drug · Device
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 18, 2025 · Synced Oct 20, 2026, 10:08 PM EDT
Completed Phase 3 Interventional

Cobalt Chromium Stent With Antiproliferative for Restenosis II Trial (COSTAR II)

NCT00165035
View directory record Official record
Conditions
Coronary Disease
Interventions
CoStar Paclitaxel Drug Eluting Coronary Stent System, TAXUS™ Express2™ Paclitaxel-Eluting Coronary Stent
Device
Lead sponsor
Cordis US Corp.
Industry
Eligibility
18 Years and older
Enrollment
1,701 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
2
States / cities
Durham, North Carolina • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 4, 2011 · Synced Oct 20, 2026, 10:08 PM EDT
Terminated Not applicable Interventional

Aesthetic Outcome of Electrodesiccation and Curettage vs Excision With Complex Linear Closure

NCT05074225
View directory record Official record
Conditions
Cutaneous Surgery
Interventions
Electrodesiccation and Curettage vs Excision
Other
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated May 24, 2024 · Synced Oct 20, 2026, 10:08 PM EDT
Completed Phase 4 Interventional Results available

Dupilumab in Adolescent and Adult Skin of Color Participants: Open-label Moderate-to-severe Eczema Trial

NCT05590585
View directory record Official record
Conditions
Moderate-to-Severe Atopic Dermatitis, Atopic Eczema
Interventions
dupilumab, Topical emollient (moisturizer)
Drug · Other
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
12 Years and older
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
30
States / cities
Birmingham, Alabama • Montgomery, Alabama • Fremont, California + 20 more
Source: ClinicalTrials.gov public record
Updated May 27, 2026 · Synced Oct 20, 2026, 10:08 PM EDT
Recruiting Phase 3 Interventional

A Study of MACI in Patients Aged 17 to 65 Years With Symptomatic Chondral or Osteochondral Defects of the Ankle

NCT06915233
View directory record Official record
Conditions
Chondral Defect, Articular Cartilage Defect
Interventions
autologous cultured chondrocytes on porcine collagen membrane, Bone Marrow Stimulation
Biological · Procedure
Lead sponsor
Vericel Corporation
Industry
Eligibility
17 Years to 65 Years
Enrollment
309 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
7
States / cities
Sacramento, California • Washington D.C., District of Columbia • Wichita, Kansas + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2026 · Synced Oct 20, 2026, 10:08 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Targeted Silica Nanoparticles for Real-Time Image-Guided Intraoperative Mapping of Nodal Metastases

NCT02106598
View directory record Official record
Conditions
Head and Neck Melanoma
Interventions
fluorescent cRGDY-PEG-Cy5.5-C dots
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2027
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Oct 20, 2026, 10:08 PM EDT
Recruiting Phase 2 Interventional

Effect of Superior Laryngeal Nerve Blocks on Patient Outcomes in Laryngeal Surgery

NCT06734975
View directory record Official record
Conditions
Vocal Cord Disease, Vocal Cord Polyp, Vocal Cord Cyst
Interventions
Superior laryngeal nerve block - Intervention (Bupivacaine and triamcinolone acetonide suspension), Superior laryngeal nerve block - Placebo (saline)
Drug
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Newark, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 15, 2026 · Synced Oct 20, 2026, 10:08 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Effects of Smoking Environments on Craving and Smoking (CameraCue2.0)

NCT02551692
View directory record Official record
Conditions
Cigarette Smoking
Interventions
Nicotine Patch, Varenicline, Placebo Nicotine Patch, Placebo Capsule
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years to 60 Years
Enrollment
125 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 18, 2020 · Synced Oct 20, 2026, 10:08 PM EDT
Withdrawn Early Phase 1 Interventional Accepts healthy volunteers

Iontophoresis in Psoriasis

NCT03979664
View directory record Official record
Conditions
Psoriasis, Psoriasis Vulgaris, Skin Diseases
Interventions
Activapatch intellidose 2.5 using active Iontophoresis, Activapatch intellidose 2.5 using inactive Iontophoresis, Dexamethasone
Device · Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 1, 2021 · Synced Oct 20, 2026, 10:08 PM EDT
Completed Phase 2 Interventional Results available

Topical Remetinostat in Treating Patient With Cutaneous Basal Cell Cancer

NCT03180528
View directory record Official record
Conditions
Skin Basal Cell Carcinoma
Interventions
Remetinostat
Drug
Lead sponsor
Kavita Sarin
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Jun 8, 2021 · Synced Oct 20, 2026, 10:08 PM EDT
Completed Phase 1 Interventional

Immunotherapy With IFx-Hu2.0 Vaccine for Advanced Non-melanoma Skin Cancers

NCT04160065
View directory record Official record
Conditions
Merkel Cell Carcinoma, Cutaneous Squamous Cell Carcinoma, Non-Melanoma Skin Cancers
Interventions
IFx-Hu2.0
Biological
Lead sponsor
TuHURA Biosciences, Inc.
Industry
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
4
States / cities
Los Angeles, California • Tampa, Florida • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2024 · Synced Oct 20, 2026, 10:08 PM EDT
Terminated Early Phase 1 Interventional

Bevacizumab (Avastin) in Unresectable/Recurrent Hemangioblastoma From Von-Hippel-Lindau Disease

NCT01015300
View directory record Official record
Conditions
Hemangioblastomas, Von Hippel Lindau Disease
Interventions
Avastin
Drug
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated May 11, 2012 · Synced Oct 20, 2026, 10:08 PM EDT
Completed Not applicable Interventional Results available

Varenicline and Motivational Advice for Smokers With Substance Use Disorders

NCT00756275
View directory record Official record
Conditions
Smoking Cessation, Nicotine Dependence
Interventions
Nicotine Replacement Treatment (NRT), varenicline, Behavioral counseling for smoking cessation
Drug · Behavioral
Lead sponsor
Brown University
Other
Eligibility
18 Years to 75 Years
Enrollment
158 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Aug 27, 2018 · Synced Oct 20, 2026, 10:08 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Office-sclerotherapy for Epistaxis Due to Hereditary Hemorrhagic Telangiectasia

NCT01408732
View directory record Official record
Conditions
Epistaxis, Hereditary Hemorrhagic Telangiectasia
Interventions
Sclerotherapy, Standard Treatment
Drug · Other
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 1, 2019 · Synced Oct 20, 2026, 10:08 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Episodic Future Thinking and Future Thinking Priming for Smoking Cessation

NCT04297332
View directory record Official record
Conditions
Tobacco-Related Carcinoma
Interventions
Behavioral Intervention, Informational Intervention, Nicotine Replacement, Telephone-Based Intervention
Behavioral · Other · Drug
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Feb 8, 2024 · Synced Oct 20, 2026, 10:08 PM EDT
Completed Phase 1 Interventional Results available

Intravaginal Artesunate for the Treatment of HPV+ High Grade Cervical Intraepithelial Neoplasia (CIN2/3)

NCT02354534
View directory record Official record
Conditions
Cervical Intraepithelial Neoplasia Grade 2/3, High-risk HPV (Any Strain)
Interventions
Artesunate Suppositories
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
3
States / cities
Baltimore, Maryland • Towson, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 28, 2021 · Synced Oct 20, 2026, 10:08 PM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Perimenopausal Estrogen Replacement Therapy Study

NCT01308814
View directory record Official record
Conditions
Perimenopause, Menopause, Depression
Interventions
Estradiol, Placebo
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
45 Years to 60 Years · Female only
Enrollment
172 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2016
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 22, 2017 · Synced Oct 20, 2026, 10:08 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Improving Parent-Child Interactions to Enhance Child Health

NCT03982511
View directory record Official record
Conditions
Child Obesity
Interventions
PCIT-Health
Behavioral
Lead sponsor
Central Michigan University
Other
Eligibility
30 Months to 84 Months
Enrollment
63 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
Mount Pleasant, Michigan
Source: ClinicalTrials.gov public record
Updated Sep 15, 2023 · Synced Oct 20, 2026, 10:08 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Trial to Evaluate the Safety of Talimogene Laherparepvec Injected Into Tumors Alone and in Combination With Systemic Pembrolizumab MK-3475-611/Keynote-611

NCT02509507
View directory record Official record
Conditions
Hepatocellular Carcinoma, Liver Metastases, Cutaneous or Subcutaneous Lymph Node, Liver Tumors
Interventions
Talimogene Laherparepvec, Pembrolizumab
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
9
States / cities
Scottsdale, Arizona • Santa Monica, California • Washington D.C., District of Columbia + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2024 · Synced Oct 20, 2026, 10:08 PM EDT
Recruiting Not applicable Interventional

Maximizing Laser Therapy Success for Port-Wine Birthmarks in Pediatric Patients

NCT07183644
View directory record Official record
Conditions
Port Wine Stains
Interventions
Pulse Dye laser, Pulse Dye Laser (PDL) pulse width stacking, Pulse Dye Laser (PDL) followed by Nd:YAG (Neodymium-doped Yttrium Aluminum Garnet laser) laser., IPL (Intense Pulsed Light) followed by Pulse Dye Laser (PDL), Cupping followed by Pulse Dye Laser (PDL)
Device
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
2 Months to 18 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
2
States / cities
Dallas, Texas • Plano, Texas
Source: ClinicalTrials.gov public record
Updated Jun 5, 2026 · Synced Oct 20, 2026, 10:08 PM EDT
Not listed Phase 3 Interventional Accepts healthy volunteers

Study of the Safety and Efficacy of DPI-386 Nasal Gel on Ocean-Going Vessels

NCT03920644
View directory record Official record
Conditions
Prevention of Nausea Associated With Motion Sickness, Treatment of Nausea Associated With Motion Sickness
Interventions
Scopolamine Transdermal Patch [Transderm Scop], Scopolamine, Placebo Patch, Placebo Gel
Drug
Lead sponsor
Naval Aeromedical Research Unit, Dayton
Federal
Eligibility
18 Years to 59 Years
Enrollment
320 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Dayton, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 19, 2019 · Synced Oct 20, 2026, 10:08 PM EDT
Not listed Phase 2 Interventional

Comparison of BioCart™II With Microfracture for Treatment of Cartilage Defects of the Femoral Condyle

NCT00729716
View directory record Official record
Conditions
Symptomatic Cartilage Defects of the Femoral Condyle
Interventions
BioCart™II, Microfracture
Biological · Procedure
Lead sponsor
ProChon Biotech Ltd
Industry
Eligibility
16 Years to 60 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
5
States / cities
Tucson, Arizona • Savannah, Georgia • Baltimore, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2012 · Synced Oct 20, 2026, 10:08 PM EDT